ETFIQData as of Nov 19, 2026. · etfiq.com/funds/lfsc

LFSC Fact Sheet: F/m Emerald Life Sciences Innovation ETF

Share
$41.58
close, Nov 20, 2026

Over the year to Nov 19, 2026, LFSC returned +24.6% in total and charged 0.54% a year.

1-year total return
+23.1%
IWV +7.4% to Nov 20, 2026
Expense ratio
0.54%
a year
Net flow, 12 months to Aug 31, 2026
+$16.2m
monthly N-PORT basis to Aug 31, 2026

Growth of $10,000, 1 year

LFSC $12,461 +24.6% · IWV $10,940 +9.4% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−2.4%
3 months−13.0%
Year to date+13.5%
1 year+23.1%
Since launch+67.0%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Travere Therapeutics Inc8.71%
Corcept Therapeutics Inc6.72%
Spyre Therapeutics Inc6.70%
LivaNova PLC6.61%
Cogent Biosciences Inc6.48%
Mirum Pharmaceuticals Inc4.32%
Billiontoone Inc3.86%
Guardant Health Inc3.81%
Cytokinetics Inc3.50%
United Therapeutics Corp3.27%

LFSC top ten by weight, 54.0% of the fund, of its 37 equity positions, from the holdings filed for Aug 31, 2026.

Facts

Holds 38 stocks in broad innovation and megatrends, 0% of its weight in S&P 500 companies · First traded Oct 31, 2024 · Benchmark Russell 3000 Total Return Index, measured by IWV, which tracks the same index

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, LFSC Fact Sheet: F/m Emerald Life Sciences Innovation ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/lfsc/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/lfsc.